NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac for Intratumoral Treatment of Prostate Cancer Read more
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization Platform Read more
XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma Read more
Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla (apremilast) in Pivotal Phase 3 Psoriasis Study Read more
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx) Read more
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity Read more
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million) Read more
EC approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer Read more
Bachem Group Webinar on Cost-efficient and Green Manufacturing of Peptides thanks to Molecular Hiving™ Technology announced Read more